Protozoan parasitic diseases, such as malaria, leishmaniasis, and trypanosomiasis, present formidable challenges to global health, particularly in resource-limited regions. Effective control and management of these diseases hinge on accurate diagnosis and timely treatment. Galectins, a family of carbohydrate-binding proteins, have garnered attention as potential targets for diagnostic and therapeutic interventions owing to their diverse roles in host-parasite interactions. This article delves into the multifaceted roles of galectins in protozoan parasitic diseases and their implications for diagnostic and therapeutic advancements. Galectins play pivotal roles in mediating host-parasite interactions throughout the parasite life cycle, influencing processes from host cell invasion to immune evasion and pathogenesis. Their differential expression in response to protozoan infections offers promise as biomarkers for infection, aiding in disease monitoring and treatment. Additionally, galectins hold therapeutic potential, with inhibitors and immunotherapies targeting galectin-mediated interactions showing promise in limiting parasite survival and enhancing the efficacy of antiparasitic treatments. However, challenges remain, including the need to elucidate specific galectin isoform roles, optimize diagnostic assays, and overcome barriers to therapeutic development. Future research endeavors aim to validate the clinical utility and efficacy of galectin-based approaches, offering prospects for improved disease control and management strategies against protozoan parasitic diseases.
HTML PDFShare this article
Malaria Control & Elimination received 1187 citations as per Google Scholar report
